Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hong kong launches massive trial to stop osteoporosis before it starts

NCT ID NCT07611097

First seen May 28, 2026 · Last updated Jun 22, 2026 · Updated 5 times

Summary

This study tests whether a structured exercise program, combined with an AI chatbot and incentives, can prevent osteoporosis and sarcopenia in adults aged 40-60. Over 8,300 participants will be randomly assigned to either the active program or standard advice. The trial will track fractures, muscle strength, and cost-effectiveness for up to 10 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOPENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Queen Mary Hospital, The University of Hong Kong, Hong Kong,

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

structured exercise program, AI chatbot, and incentives

What this could lead to

If successful, this could provide a proven, cost-effective way to prevent fractures and muscle loss in middle-aged adults, reducing the need for medication.

What could go wrong

This is a large but early-stage prevention trial. The intervention is behavioral, so results depend on long-term adherence. It may not show significant benefits over standard advice.

Conditions

The condition(s) this trial relates to.

osteoporosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.